Featured Press Releases

SHINE Technologies Showcases FLARE™, the World

SHINE Technologies Showcases FLARE™, the World's Most Powerful Continuous Fusion Neutron System

ProteoNic unveils Early Access Program, boosting viral vector titers with LV-2G UNic® technology

ProteoNic unveils Early Access Program, boosting viral vector titers with LV-2G UNic® technology

  • 24 Mar 2024

ProteoNic Biosciences, a leading provider of premium vector technology and services for the...

ChromaDex expands its pharmaceutical-grade Niagen® IV and injection offerings to more leading wellness clinics.

ChromaDex expands its pharmaceutical-grade Niagen® IV and injection offerings to more leading wellness clinics.

Rigaku Analytical Devices Partners with Leading Pharmaceutical Supplier

Rigaku Analytical Devices Partners with Leading Pharmaceutical Supplier

LOTUS study data on DAYBUE® (trofinetide) for Rett Syndrome

LOTUS study data on DAYBUE® (trofinetide) for Rett Syndrome's long-term efficacy and tolerability is published in Developmental Medicine and Child Neurology

In Europe, Samsung Bioepis begins the commercialization of BYOOVIZ®, a biosimilar to Lucentis (Ranibizumab)

In Europe, Samsung Bioepis begins the commercialization of BYOOVIZ®, a biosimilar to Lucentis (Ranibizumab)

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.

  • Johnson & Johnson
  • 06 Mar 2026
ulrich medical USA® Expands Commitment to Evidence-Based Spine Innovation; Appoints Alissa Calaway, RN, MSN as Director of U.S. Clinical Affairs

ulrich medical USA® Expands Commitment to Evidence-Based Spine Innovation; Appoints Alissa Calaway, RN, MSN as Director of U.S. Clinical Affairs

  • ulrich medical USA
  • 06 Mar 2026
Cognito Therapeutics Announces $105 Million Oversubscribed Series C Financing to Advance Spectris™ in Alzheimer’s Disease.

Cognito Therapeutics Announces $105 Million Oversubscribed Series C Financing to Advance Spectris™ in Alzheimer’s Disease.

  • Cognito Therapeutics
  • 05 Mar 2026
Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

  • Eton Pharmaceuticals
  • 04 Mar 2026
FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

  • US-Rx
  • 03 Mar 2026
30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

  • Merck & Co., Inc.
  • 03 Mar 2026
World Drug Delivery Summit 2025
The Digital Pharma Advances Conference 2026

Most Popular
March   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.